Navigation Links
Beta-blockers help reduce metastasis and improve survival in breast cancer patients
Date:3/26/2010

Barcelona, Spain: Treatment with beta-blockers can help reduce the spread of cancer in patients with breast tumours, a researcher will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday). In a controlled study, Dr. Des Powe, a senior healthcare research scientist at Queen's Medical Centre, Nottingham University Hospital NHS Trust, Nottingham, UK, and his team found that the group of patients treated with beta-blockers showed a significant reduction in metastasis and better survival. The scientists believe that they are the first in the world to have investigated the effect of beta-blockers in breast cancer patients.

In collaboration with Professor Frank Entschladen's group at Witten University, Germany, Dr. Powe looked at three groups of breast cancer patients: those who were already being treated for hypertension by beta-blockers, those whose hypertension was treated by other medications, and those who did not suffer from hypertension and were therefore not taking any treatment for it. Forty-three of the 466 patients were already taking beta-blockers and, in this group, there were significant reductions in both distant metastasis and local recurrence. They also had a 71% reduced risk of dying from breast cancer compared with the other groups.

"We were also able to study the presence of one receptor for beta-blockers, β2AR, as a potential biomarker for predicting clinical response to beta-blocker treatment," says Dr. Powe, "but we did not find that this correlated directly to the outcome of treatment. We are currently looking at other target receptors as predictors of clinical outcome."

Previous cell line laboratory studies have shown that beta-blockers work against various types of cancer because high levels of stress hormones in the tumour increase cell proliferation and migration (the movement of cells to other locations). "These effects are induced by the stress hormones norepinephrine and epinephrine acting on specific target receptors in a kind of lock and key fashion," says Dr. Powe. "We sought to translate these laboratory findings into clinical research."

Beta-blocker drugs bind to a specific kind of receptor to prevent the stress hormones from reaching their target; in cancer cells this prevents the hormones from stimulating and activating them. The researchers say that they are sure that their results are due to the effect of beta-blockers rather than a protective effect of hypertension per se.

"If that had been the case, we would have seen similar survival benefits in patients receiving other forms of treatment for hypertension," says Dr. Powe, "but we did not. It is reasonable to speculate, therefore, that some non-hypertensive women with breast cancer will respond favourably to beta-blocker treatment, though doses and side effects would need to be investigated in clinical trials. We also need to look at whether beta-blockers could be given as a supplementary therapy with existing breast cancer treatment."

This finding may assist treatment in two ways, say the researchers: it appears to slow down tumour growth and could also be used to target those patients who have an increased risk of developing secondary cancers.

"Our first study is relatively small, and we now intend to validate it in a larger group," says Dr. Powe. "We will be looking for funding and collaborators to test the effectiveness of beta-blocker treatment on patients diagnosed with breast cancer. We are very encouraged by these first results which have already shown that by using a well-established, safe, and cost-effective drug, we can take another step on the road to targeted therapy in breast cancer."


'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Stronger Ozone Standard Could Dramatically Reduce Asthma, Premature Deaths
2. Report documents statewide initiative to reduce near-term scheduled births
3. Gladstone scientists identify target that may reduce complications of obesity
4. Unique Clean Energy Program Helps Hospitals Buy Clean Energy, Reduce Costs and Counteract Climate Change
5. King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain
6. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
7. Abstinence-Only Classes Reduced Sexual Activity, Study Found
8. Study finds reduced brain gray matter concentration in patients with severe obstructive sleep apnea
9. CT Scans Reduce Unneeded Appendectomies in Women
10. Omega-3 Supplements Dont Reduce Risk of Preterm Birth
11. Attendance at Alcoholics Anonymous meetings may reduce depression symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... Journal of Oral Implantology – Tooth loss ... overall dental health, including complications with speech, eating, and overcompensation of mouth due to ... lost teeth. As the number of tooth replacements increase, it is imperative to design ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and CEO ... Enterprising Women magazine as one of its 2017 Enterprising Women of the Year, ... have demonstrated that they have fast-growth businesses, mentor or actively support other women ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you ... to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to the ... level because the body recognizes its raw form (unlike the synthetically made options that ...
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... 25, 2017 , ... Coalition Duchenne, a ... muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on positive ... trial in Duchenne announced today. , Coalition Duchenne funded studies carried out ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology: